B
1.81
-0.19 (-9.50%)
| Previous Close | 2.00 |
| Volume | 10,872 |
| Price / Sales | 0.330 |
| 52 Weeks Range |
| Operating Margin (TTM) | -610.00% |
| Diluted EPS (TTM) | -1.22 |
| Total Debt/Equity (MRQ) | 101.28% |
| Current Ratio (MRQ) | 2.35 |
| Operating Cash Flow (TTM) | -57.40 M |
| Levered Free Cash Flow (TTM) | -34.48 M |
| Return on Assets (TTM) | -65.79% |
| Return on Equity (TTM) | -246.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | BioAtla, Inc. | Mixed | Mixed |
AIStockmoo Score
| Value 35% | -1.5 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | -1.5 |
| Timing 35% | 2.2 |
| AI Technical info | NA |
| Technical Oscillators info | 2.0 |
| Technical Moving Averages info | 2.5 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| Environment | ×0.79 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -17.9% |
| Pillar Agreement | ×0.84 |
| Not in score | |
| Price Volatility info | -0.3 |
| Final Score | 0.16 |
Select this tab to load the latest available analysis.
|
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.66% |
| % Held by Institutions | 32.52% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |